Caplin Point Labs' subsidiary inks distribution pact with Xellia Pharma for 5 injectables in US

The first product is expected to be launched shortly, while approvals for the remaining are expected in the next 12-18 months, Caplin Point Laboratories said in a BSE filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2O3OseI
via IFTTT